Alpa Laboratories share price, P/E, ROE & financials

As of 6 Nov 2026, Alpa Laboratories trades at 32.0× trailing earnings, above the industry P/E of 28.7×, and the shares are 42% below their 52-week high. Its ROCE of 8.8% is the lowest among the 7 largest Drug Manufacturers (Specialty & Generic) peers, and sales and net profit grew 4.3% and 6.1% a year over 3 years. The company has almost no debt. It is a small-cap company with a market cap of ₹113 Cr, ranked 116th of 154 Drug Manufacturers (Specialty & Generic) companies by market cap; the shares fell 39% over the past year.

As of 6 Nov 2026Prices are delayed about 15 minutes; fundamentals are from the quarter ended Jun 2026.How we calculate this

past year

Open: ₹54.49
Day high: ₹54.49
Day low: ₹51.71
Prev. close: ₹54.46
Volume: 8K

Health check

1 fair · 5 to check

ReturnsBehind
−39.0% over a year, better than 0 of 7 peers.
Price tagIn line
P/E 32.0 vs industry 28.7.
GrowthSlow
Sales +4.3%, profit +6.1% a year over 3 years.
ProfitabilityWeak
ROCE 8.8% vs peer median 17.9%.
Balance sheetStretched
Practically debt-free, Piotroski 3 of 9.
Red flags2 to check
Quarterly profit down 91.7% on a year ago.

Compared with 7 industry peers. Computed from reported figures. Educational, not a recommendation.

Drug Manufacturers - Specialty & Generic

153 listed peers. Screen the industry

Small cap

₹113 Cr, #116 of 154 in its industry by size.

Moves with the market

Beta 0.98 vs the NIFTY 50: tracks the market closely.

Key metrics

Last 12 months to Jun 2026: sales ₹111 Cr · profit ₹4 Cr

Market cap: ₹113 Cr; Small cap
P/E: 32.0; Industry 28.7
Price to book: 0.61; Peers 4.99
Dividend yield: 0.00%
ROE: 8.4%; Peers 14.7%
ROCE: 8.8%; Peers 17.9%
Debt to equity: 0.01; Debt ₹2.51 Cr
EPS (TTM): ₹1.68; Face value ₹10
OPM (TTM): −1.0%; Net margin 3.8%
Sales growth: +25.2%; Latest quarter vs a year ago
Profit growth: −91.7%; Latest quarter vs a year ago
Price to sales: 1.02; EV/EBITDA 21.7

Strengths

Practically debt-free.
Quarterly sales up 25.2% on a year ago.
Positive operating cash flow in each of the last 4 years.

Risks to check

Quarterly profit down 91.7% on a year ago.
42% below its 52-week high.

Derived automatically from reported figures. Not a recommendation.

About Alpa Laboratories

Alpa Laboratories Limited engages in the manufacture and sale of drugs and chemicals in India. It offers ethical, generic, and over the counter medicines. The company provides tablets, capsules, injections, syrups, ointments, creams, eye drops, and other dosage forms for human and veterinary healthcare, as well as aquaculture products, including probiotics, deodorizer, minerals, feed supplements, and disinfectant. The company was founded in 1967 and is…

Headquarters: Indore
Employees: 457
Sector: Healthcare
ISIN: INE385I01010
Website: alpalabs.in

Price range

52 weeks

₹46.10₹92.50

Today

₹51.71₹54.49

Avg volume (3M): 16.2K
1-year return: minus 39.0%
From 52-week high: minus 41.9%

Peers · Drug Manufacturers - Specialty & Generic

Compare with peers Screen the whole industry

Company
SUNPHARMASun Pharmaceutical Industries	1,860.00	plus 1.69%	4,46,276	40.7	4.99	17.9%	13.1%	28.2%	10.4%	10.6%	0.86%	plus 8.2%
DIVISLABDivi's Laboratories	10,320.50	plus 1.78%	2,73,977	93.6	16.35	19.0%	16.2%	34.9%	11.0%	12.1%	0.29%	plus 49.0%
TORNTPHARMTorrent Pharmaceuticals	4,750.00	plus 0.85%	1,80,675	80.2	9.83	9.1%	15.7%	33.7%	13.3%	20.2%	0.80%	plus 31.7%
LAURUSLABSLaurus Labs	2,340.00	minus 0.26%	1,26,433	94.4	20.86	19.5%	24.0%	30.4%	3.8%	4.0%	0.09%	plus 138.6%
ZYDUSLIFEZydus Lifesciences	1,197.90	plus 0.41%	1,19,491	28.6	4.29	19.0%	14.7%	26.2%	16.5%	37.0%	0.08%	plus 22.8%
DRREDDYDr. Reddy's Laboratories	1,373.00	plus 0.51%	1,14,462	40.9	2.96	14.2%	7.3%	15.9%	11.0%	−1.7%	0.58%	plus 13.8%
CIPLACipla	1,411.00	plus 0.49%	1,13,993	39.4	3.22	14.9%	8.3%	17.3%	7.2%	11.5%	0.92%	minus 6.6%
ALPAAlpa Laboratories	53.74	minus 1.32%	113	32.0	0.61	8.8%	8.4%	−1.0%	4.3%	6.1%	0.00%	minus 39.0%
Median of 7 peers	–	0.51%	1,26,433	40.9	4.99	17.9%	14.7%	28.2%	11.0%	11.5%	0.58%	22.8%

Quarterly results

Consolidated, ₹ crore

SalesSelect a row below to chart it

Jun 25	Sep 25	Dec 25	Mar 26	Jun 26
19.1	26.3	29	31.4	23.9
18.7	28.5	27.5	27.8	27.9
0.4	−2.2	1.5	3.6	−4
2.2%	−8.5%	5.2%	11.5%	−16.5%
11.9	3.1	0.9	−0.2	5.8
0	0	0	0.1	0.1
0.6	0.7	0.6	0.2	0.7
11.8	0.1	1.7	3.1	1
–	–	−8.9%	55.0%	–
11.8	0.1	1.9	1.4	1
5.59	0.05	0.90	0.24	0.49

Profit & loss

Yearly, ₹ crore

Sales CAGR 3Y: +4.3%
Profit CAGR 3Y: +6.1%
EPS CAGR 3Y: +6.7%
ROE: 8.4%

Net profitSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
92.4	108	112	105
–	+16.8%	+3.4%	minus 6.0%
83.7	98.2	106	101
8.7	9.7	5.7	3.9
9.4%	9.0%	5.1%	3.7%
5.9	4.6	3.4	3.5
0.1	0.3	0	0
1.3	2	2.2	2.1
2.7	8.6	18.9	11.4
15.9	20.7	25.7	16.7
20.8%	18.9%	24.0%	10.1%
12.6	16.8	19.5	15
–	+33.3%	+16.3%	minus 23.0%
5.88	7.97	9.27	7.13

Forecast

Your assumptions, not a prediction

Balance sheet

At each financial year end, ₹ crore

Total assetsSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
21	21	21	21
114	131	150	165
2.3	5.2	0	2.5
30.4	25.2	51.2	53.4
167	182	223	242
7	11.4	21.3	20.1
1.3	1.4	1.4	1.4
80.8	92.9	113	138
78.1	76.7	87.2	82.7
167	182	223	242

Cash flow

Yearly, ₹ crore

Cash from operationsSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
8.9	3.6	18.3	9.3
2.1	−13.3	−12.4	−10.9
−3.8	2.6	−5.4	2.2
7.2	−7.1	0.5	0.6
−1.1	−6.4	−11.4	−3.2
7.8	−2.7	6.9	6

Shareholding pattern

Source: NSE filings

NSE hasn’t returned a shareholding pattern for this company.

Major shareholders

NSE filing

Filings & events

News

No recent news coverage found.

My notes

Private to you